1. Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., Campagna, E., & Newcomer, J. W. (2010). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics & Adolescent Medicine 164(4), 344–351. https://doi.org/10.1001/archpediatrics.2010.48
2. McKinney, C., & Renk, K. (2011). Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clinical Psychology Review 31(3), 465–471. https://doi.org/10.1016/j.cpr.2010.11.005
3. Cooper, W. O., Hickson, G. B., Fuchs, C., Arbogast, P. G., & Ray, W. A. (2004). New users of antipsychotic medications among children enrolled in TennCare. Archives of Pediatric & Adolescent Medicine 158(8), 753–759. https://doi.org/10.1001/archpedi.158.8.753
4. Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 63(6), 679–685. https://doi.org/10.1001/archpsyc.63.6.679
5. Crystal, S., Olfson, M., Huang, C., Pincus, H., & Gerhard, T. (2009). Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs (Project Hope) 28(5), w770–w781. https://doi.org/10.1377/hlthaff.28.5.w770
6. Correll, C. U., Kratochvil, C. J., & March, J. S. (2011). Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. The Journal of Clinical Psychiatry 72(5), 655–670. https://doi.org/10.4088/JCP.11r07064
7. Andrade, S. E., Lo, J. C., Roblin, D., Fouayzi, H., Connor, D. F., Penfold, R. B., Chandra, M., Reed, G., & Gurwitz, J. H. (2011). Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics 128(6), 1135–1141. https://doi.org/10.1542/peds.2011-0855
8. Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., Fuchs, D. C., & Ray, W. A. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 70(10),1067–1075. https://doi.org/10.1001/jamapsychiatry.2013.2053
9. Correll, C. U. (2008). Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. FOCUS: The Journal of Lifelong Learning in Psychiatry 6(3), 368–378. https://doi.org/10.1176/foc.6.3.foc368
10. Seida, J. C., Schouten, J. R., Boylan, K., Newton, A. S., Mousavi, S. S., Beaith, A., Vandermeer, B., Dryden, D. M., & Carrey, N. (2012). Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 129(3), e771–e784. https://doi.org/10.1542/peds.2011-2158
11. Olfson, M., Kroenke, K., Wang, S., & Blanco C. (2014). Trends in office-based mental health care provided by psychiatrists and primary care physicians. The Journal of Clinical Psychiatry 75(3), 247–253. https://doi.org/10.4088/JCP.13m08834
12. Aparasu, R. R., & Bhatara, V. (2007). Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Current Medical Research and Opinion 23(1), 49–56. https://doi.org/10.1185/030079906X158075
13. Jensen, P. S., Hinshaw, S. P., Swanson, J. M., Greenhill, L. L., Conners, C. K., Arnold, L. E., Abikoff, H. B., Elliott, G., Hechtman, L., Hoza, B., March, J. S., Newcorn, J. H., Severe, J. B., Vitiello, B., Wells, K., & Wigal, T. (2001). Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics 22(1), 60–73. https://doi.org/10.1097/00004703-200102000-00008
14, Eyberg, S. M., Nelson, M. M., & Boggs, S. R. (2008). Evidence-based psychosocial treatments for children and adolescents with disruptive behavior. Journal of Clinical Child and Adolescent Psychology: The Official Journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53 37(1), 215–237. https://doi.org/10.1080/15374410701820117
15. Schimmelmann, B. G., Schmidt, S. J., Carbon, M., & Correll, C. U. (2013). Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Current Opinion in Psychiatry 26(2), 219–230. https://doi.org/10.1097/YCO.0b013e32835dcc2a
16. Kealey, E., Scholle, S. H., Byron, S. C., Hoagwood, K., Leckman-Westin, E., Kelleher, K., & Finnerty, M. (2014). Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines. Academic Pediatrics 14(5 Suppl), S68–S75. https://doi.org/10.1016/j.acap.2014.05.009
17. National Committee for Quality Assurance. (n.d.) HEDIS Measures for the Safe & Judicious Use of Antipsychotic Medications in Children and Adolescents. Retrieved May 1, 2020, from https://www.ncqa.org/hedis/reports-and-research/national-collaborative-for-innovation-in-quality-measurement/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents/.
18. American Academy of Child and Adolescent Psychiatry. (n.d.) Practice Parameter for the Use of Atypical Antipsychotic Medications in Children and Adolescents. Retrieved July 12, 2012, from https://www.aacap.org//App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf.
19. Steinman, K. J., Shoben, A. B., Dembe, A. E., & Kelleher, K. J. (2015). How Long Do Adolescents Wait for Psychiatry Appointments? Community Mental Health Journal 51(7), 782–789. https://doi.org/10.1007/s10597-015-9897-x
20. Olin, S. C., O'Connor, B. C., Storfer-Isser, A., Clark, L. J., Perkins, M., Hudson Scholle, S., Whitmyre, E. D., Hoagwood, K., & Horwitz, S. M. (2016). Access to Care for Youth in a State Mental Health System: A Simulated Patient Approach. Journal of the American Academy of Child and Adolescent Psychiatry 55(5), 392–399. https://doi.org/10.1016/j.jaac.2016.02.014
21. Gallo, K. P., Olin, S. S., Storfer-Isser, A., O'Connor, B. C., Whitmyre, E. D., Hoagwood, K. E., & Horwitz, S. M. (2017). Parent Burden in Accessing Outpatient Psychiatric Services for Adolescent Depression in a Large State System. Psychiatric services (Washington, D.C.) 68(4), 411–414. https://doi.org/10.1176/appi.ps.201600111
22. Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J., & CAMESA guideline group (2011). Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry 20(3), 218–233.
23. Zeier, K., Connell, R., Resch, W., & Thomas, C. J. (2013). Recommendations for lab monitoring of atypical antipsychotics. Current Psychiatry 12(9), 51–54.
24. Hilt, R. J., Barclay, R. P., Bush, J., Stout, B., Anderson, N., & Wignall, J. R. (2015). A Statewide Child Telepsychiatry Consult System Yields Desired Health System Changes and Savings. Telemedicine Journal and e-Health: The Official Journal of the American Telemedicine Association 21(7), 533–537. https://doi.org/10.1089/tmj.2014.0161
25. Brunette, M. F., Cotes, R. O., de Nesnera, A., McHugo, G., Dzebisashvili, N., Xie, H., & Bartels, S. J. (2018). Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy. Psychiatric services (Washington, D.C.) 69(9), 1021–1028. https://doi.org/10.1176/appi.ps.201700536
26. Quinn, A. E., Reif, S., Evans, B., Creedon, T. B., Stewart, M. T., Garnick, D. W., & Horgan, C. M. (2016). How health plans promote health IT to improve behavioral health care. The American Journal of Managed Care 22(12), 810–815.
27. New York State Department of Health. About eQARR 2018. Retrieved June 1, 2020, from https://www.health.ny.gov/health_care/managed_care/reports/eqarr/2018/about.htm.
28. Carman, K. L., Dardess, P., Maurer, M., Sofaer, S., Adams, K., Bechtel, C., & Sweeney, J. (2013). Patient and family engagement: a framework for understanding the elements and developing interventions and policies. Health Affairs (Project Hope) 32(2), 223–231. https://doi.org/10.1377/hlthaff.2012.1133
29. McClellan, J., Kowatch, R., Findling, R. L., & Work Group on Quality Issues (2007). Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 46(1), 107–125. https://doi.org/10.1097/01.chi.0000242240.69678.c4
30. Steiner, H., Remsing, L., & Work Group on Quality Issues (2007). Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry 46(1), 126–141. https://doi.org/10.1097/01.chi.0000246060.62706.af
31. American Academy of Child and Adolescent Psychiatry (2001). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry 40(7 Suppl), 4S–23S. https://doi.org/10.1097/00004583-200107001-00002
32. Gleason, M. M., Egger, H. L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. F., Luby, J. L., Owens, J., Scahill, L. D., Scheeringa, M. S., Stafford, B., Wise, B., & Zeanah, C. H. (2007). Psychopharmacological treatment for very young children: contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry 46(12), 1532–1572. https://doi.org/10.1097/chi.0b013e3181570d9e
33. Scotto Rosato, N., Correll, C. U., Pappadopulos, E., Chait, A., Crystal, S., Jensen, P. S., & Treatment of Maladaptive Aggression in Youth Steering Committee (2012). Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics 129(6), e1577–e1586. https://doi.org/10.1542/peds.2010-1361
34. Pappadopulos, E., Macintyre li, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., Schooler, N., Sikich, L., Greenhill, L., Schur, S. B., Felton, C. J., Kranzler, H., Rube, D. M., Sverd, J., Finnerty, M., Ketner, S., Siennick, S. E., & Jensen, P. S. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. Journal of the American Academy of Child and Adolescent Psychiatry 42(2), 145–161. https://doi.org/10.1097/00004583-200302000-00008
35. Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J., & Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group (2011). Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics & Child Health 16(9), 581–589.
36. Texas Department of Family and Protective Services and The University of Texas at Austin College of Pharmacy. (September 2013). Psychotropic Medication Utilization Parameters for Foster Children. Retrieved October 22, 2013, from https://www.dfps.state.tx.us/Child_Protection/Medical_Services/documents/reports/2013-09_Psychotropic_Medication_Utilization_Parameters_for_Foster_Children.pdf.
37. Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., Elbarbary, M., Post, P., Nasser, M., Shukla, V., Jaeschke, R., Brozek, J., Djulbegovic, B., & Guyatt, G. (2013). GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. Journal of Clinical Epidemiology 66(7), 726–735. https://doi.org/10.1016/j.jclinepi.2013.02.003
38. Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., Schünemann, H. J., & GRADE Working Group (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 336(7650), 924–926. https://doi.org/10.1136/bmj.39489.470347.AD
39. Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working Group. (2011). The Oxford 2011 Levels of Evidence. 2011. Retrieved October 12, 2013, from https://www.cebm.ox.ac.uk/resources/levels-of-evidence.
